Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.

Rozeboom B, Dey N, De P.

Am J Cancer Res. 2019 Dec 1;9(12):2821-2831. eCollection 2019. Review.

2.

Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.

De P, Dey N.

Int J Mol Sci. 2019 Nov 15;20(22). pii: E5732. doi: 10.3390/ijms20225732. Review.

3.

RAC1 Takes the Lead in Solid Tumors.

De P, Aske JC, Dey N.

Cells. 2019 Apr 26;8(5). pii: E382. doi: 10.3390/cells8050382. Review.

4.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

5.

Decision making in precision oncology: an issue of mutational contextuality.

Dey N, De P.

Am J Cancer Res. 2019 Mar 1;9(3):628-629. eCollection 2019. No abstract available.

7.

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators.

Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum in: Lancet Respir Med. 2019 Jan;7(1):e1.

PMID:
30416083
8.

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells.

De P, Carlson JH, Leyland-Jones B, Williams C, Dey N.

Sci Rep. 2018 Sep 4;8(1):13192. doi: 10.1038/s41598-018-31575-3.

9.

Promise of Precision Medicine in Cancers: Lessons Learned.

Dey N, Williams C, Leyland-Jones B, De P.

S D Med. 2017 Nov;70(11):486-490. No abstract available.

PMID:
29088519
10.

Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient.

Xu B, Krie A, De P, Williams C, Elsey R, Klein J, Leyland-Jones B.

Cureus. 2017 Jun 29;9(6):e1408. doi: 10.7759/cureus.1408.

11.

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.

12.

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Dey N, Krie A, Klein J, Williams K, McMillan A, Elsey R, Sun Y, Williams C, De P, Leyland-Jones B.

Int J Mol Sci. 2017 Jun 7;18(6). pii: E1218. doi: 10.3390/ijms18061218.

13.

Mutation matters in precision medicine: A future to believe in.

Dey N, Williams C, Leyland-Jones B, De P.

Cancer Treat Rev. 2017 Apr;55:136-149. doi: 10.1016/j.ctrv.2017.03.002. Epub 2017 Mar 16. Review.

PMID:
28371665
14.

Larval infestation in a common Pariah Kite Milvus migrans (Boddaert).

Sinha SK, Sinha AK, De P, Bhakat S.

J Parasit Dis. 2017 Mar;41(1):199-201. doi: 10.1007/s12639-016-0777-2. Epub 2016 Mar 21.

15.

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.

Dey N, De P, Leyland-Jones B.

Pharmacol Ther. 2017 Jul;175:91-106. doi: 10.1016/j.pharmthera.2017.02.037. Epub 2017 Feb 16. Review.

PMID:
28216025
16.

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.

De P, Carlson JH, Jepperson T, Willis S, Leyland-Jones B, Dey N.

Oncotarget. 2017 Jan 10;8(2):3072-3103. doi: 10.18632/oncotarget.13618.

17.

Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy.

Abramovitz M, Krie A, Dey N, De P, Williams C, Leyland-Jones B.

Curr Opin Oncol. 2016 Nov;28(6):461-468. Review.

PMID:
27606693
18.

Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.

De P, Carlson JH, Wu H, Marcus A, Leyland-Jones B, Dey N.

Oncotarget. 2016 Jul 12;7(28):43124-43149. doi: 10.18632/oncotarget.8988.

19.

Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Dey N, Sun Y, Carlson JH, Wu H, Lin X, Leyland-Jones B, De P.

Am J Cancer Res. 2016 Mar 15;6(4):714-46. eCollection 2016.

20.

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Dey N, De P, Brian LJ.

Am J Transl Res. 2015 Oct 15;7(10):1675-98. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center